Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant <i>Enterococcus faecalis</i> isolates.

ABSTRACT: Despite the use of recommended treatments against Enterococcus faecalis infective endocarditis, mortality rates remain at 30%. Penicillin-resistant, ampicillin-susceptible E. faecalis (PRASEF) has been associated with worsened clinical outcomes; however, a more common phenotype, borderline-PRASEF (penicillin minimum inhibitory concentration [MIC] 4-8 µg/mL), decreases the activity of ampicillin-ceftriaxone in vitro. Ceftobiprole presents a promising alternative against borderline-PRASEF and also has shown activity against vancomycin-resistant E. faecalis (VREfs). The ceftobiprole MIC distribution was determined via broth microdilution for 78 E. faecalis clinical blood isolates, including 71 borderline-PRASEF. Ceftobiprole activity alone was compared to am

SUBMITTER: Funk OG 

PROVIDER: S-EPMC12777555 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature